Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > December 4, 2024
Daily News
December 4, 2024
- (Update) Average NHI-Market Price Gap Narrows to 5.2% to Hit Record Low
December 4, 2024
- Medipal, JCR Kick Off Japan PI/II of MPS IIIB Therapy
December 4, 2024
- Ono Teams Up with Canada’s Congruence in Cancer Drug Discovery
December 4, 2024
- Australia Accepts Shionogi’s NDA for Antibiotic Cefiderocol
December 4, 2024
- LDP Sees Growing Chorus of Opposition to Off-Year Revisions
December 4, 2024
- Japan Expected to Include Shingles Vaccines in NIP from FY2025
December 4, 2024
- Forxiga Crowned in HP Market Promotion Ranking in October: Intage
December 4, 2024
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…